Drug Trial Radar · NCT03781167
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
Last checked: Nov 19, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
Apr 29, 2019
Primary completion
Aug 17, 2022
Study completion Aug 17, 2022
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.
Conditions
- Parkinson's Disease (PD)
Interventions
ABBV-951Drug
Solution for continuous subcutaneous infusion (CSCI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)
- Number of Participants With Adverse Events of Special InterestTime frame: From first dose of study drug until 30 days following last dose of study drug (up to 480 days)
- Number of Participants With Numeric Grade Equal to or Higher Than 5 and With Letter Grade Equal to or Higher Than D on the Infusion Site Evaluation ScaleTime frame: Day 1, Day 2, Week 1, Week 2, Week 3, Week 4, Week 6, Week 13, Week 26, Week 39, and Week 52
- Hematocrit (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Hemoglobin (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Red Blood Cell (RBC) Count (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- White Blood Cell (WBC) Count (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Neutrophils (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Lymphocytes (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Monocytes (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Absolute Platelet Count (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Mean Corpuscular Hemoglobin (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Mean Corpuscular Volume Concentration (MCHC) (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Prothrombin Time (PT) (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Activated Partial Thromboplastin Time (Hematology): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Blood Urea Nitrogen (BUN) (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Creatinine (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Creatine Phosphokinase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Total Bilirubin (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Serum Alanine Aminotransferase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Serum Aspartate Aminotransferase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Serum Lactate Dehydrogenase (LDH) (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Gamma-glutamyl Transferase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Alkaline Phosphatase (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Sodium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Potassium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Calcium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Inorganic Phosphorus (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Uric Acid (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Total Cholesterol (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Albumin (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Glucose (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Sodium Bicarbonate/CO2 (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Magnesium (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Creatinine Clearance (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Homocysteine (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, and 52
- Vitamin B6 (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, and 52
- Vitamin B12 (Clinical Chemistry): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, and 52
- pH (Urinalysis): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Specific Gravity (Urinalysis): Change From Baseline to End of StudyTime frame: Baseline, Weeks 6, 26, 39, and 52
- Orthostatic Systolic Blood Pressure (Vital Signs): Change From Baseline to End of StudyTime frame: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)
- Orthostatic Diastolic Blood Pressure (Vital Signs): Change From Baseline to End of StudyTime frame: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)
- Orthostatic Pulse Rate (Vital Signs): Change From Baseline to End of StudyTime frame: Baseline, Weeks 1, 6, 26, and 52 (orthostatic and standing); Baseline, Weeks 2, 4, 13, and 39 (supine)
- Electrocardiogram (ECG) Mean Heart Rate: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
- Electrocardiogram (ECG) Aggregate PR Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
- Electrocardiogram (ECG) Aggregate QRS Duration: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
- Electrocardiogram (ECG) Aggregate QT Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
- Electrocardiogram (ECG) Aggregate QTcB Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
- Electrocardiogram (ECG) Aggregate QTcF Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
- Electrocardiogram (ECG) Aggregate RR Interval: Change From Baseline to End of StudyTime frame: Baseline, Day 1 (postdose), Weeks 6 and 52
Locations
65 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Main /ID# 207996
Birmingham, Alabama
Banner Sun Health Res Inst /ID# 208811
Sun City, Arizona
The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 216126
Fountain Valley, California
University of Colorado Hospital /ID# 207968
Aurora, Colorado
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 207677
Boca Raton, Florida
Northwestern University Feinberg School of Medicine /ID# 208812
Chicago, Illinois
Indiana Clinical Research Cent /ID# 207952
Indianapolis, Indiana
Univ Kansas Med Ctr /ID# 208963
Kansas City, Kansas
University of Kentucky Chandler Medical Center /ID# 207603
Lexington, Kentucky
Massachusetts General Hospital /ID# 207993
Boston, Massachusetts
Health Partners /ID# 207950
Saint Paul, Minnesota
University of Missouri /ID# 209043
Columbia, Missouri
Washington University-School of Medicine /ID# 207525
St Louis, Missouri
Dartmouth-Hitchcock Medical Center /ID# 207972
Lebanon, New Hampshire
Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 209784
Raleigh, North Carolina
Legacy Medical Group - Neurology /ID# 208031
Portland, Oregon
Prisma Health Cancer Institute-Faris Road /ID# 207650
Greenville, South Carolina
Neurology Consultants of Dallas - LBJ Fwy /ID# 207619
Dallas, Texas
Baylor College of Medicine /ID# 207620
Houston, Texas
Central Texas Neurology Consul /ID# 216918
Round Rock, Texas
Univ Texas HSC San Antonio /ID# 208958
San Antonio, Texas
Booth Gardner Parkinson's Care Center /ID# 208026
Kirkland, Washington
Inland Northwest Research /ID# 208122
Spokane, Washington
Medical College of Wisconsin /ID# 207999
Milwaukee, Wisconsin
Concord Repatriation General Hospital /ID# 207628
Concord, New South Wales, Australia
Westmead Hospital /ID# 207633
Westmead, New South Wales, Australia
Royal Adelaide Hospital /ID# 207634
Adelaide, South Australia, Australia
Alfred Health /ID# 207632
Melbourne, Victoria, Australia
Perron Institute /ID# 207627
Nedlands, Western Australia, Australia
AZ Sint-Jan Brugge /ID# 208178
Bruges, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 208177
Liège, Belgium
Universitair Ziekenhuis Leuven /ID# 209058
Leuven, Vlaams-Brabant, Belgium
University of Calgary - Movement Disorders Clinic /ID# 207342
Calgary, Alberta, Canada
Centre de Recherche St-Louis /ID# 207344
Québec, Quebec, Canada
Bispebjerg and Frederiksberg Hospital /ID# 207669
Copenhagen NV, Capital Region, Denmark
Aarhus University Hospital /ID# 207668
Aarhus N, Central Jutland, Denmark
Odense University Hospital /ID# 207871
Odense C, Region Syddanmark, Denmark
Kliniken Beelitz GmbH /ID# 208600
Beelitz-Heilstätten, Germany
InnKlinikum Haag /ID# 208601
Haag, Germany
Universitaetsklinikum Ulm /ID# 208602
Ulm, Baden-Wurttemberg, Germany
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.